UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person * Harvey Jimmie				2. Issuer Name and Ticker or Trading Symbol Fortress Biotech, Inc. [FBIO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O FORTRESS BIOTECH, INC., 2 GANSEVOORT STREET, 9TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 01/01/2019							Office	er (give title belo	ow)	Other (spec	ify belo	w)	
NEW YO	ORK, NY	(Street) 10014		4. If An	nendment,	Date	Origin	al File	ed(Month/	Day/Year)		_X_ Form fi	led by One Rep	Group Filing orting Person n One Reporting		licable l	Line)
(City		(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, o							osed of, or	Beneficially	Owned				
(Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if		(Instr. 8)		(A) or Disposed o		of (D) Benefic Reporte		unt of Securities ially Owned Following d Transaction(s)		Form:	nip of B	7. Nature of Indirect Beneficial	
				(Month/Day/Year)			Code	V	Amoun	(A) or (D)	Price	Ì	nstr. 3 and 4)		Direct (I or Indire (I) (Instr. 4)	Indirect (Instr.	
COMMON STOCK, PAR VALUE \$0.001		01/01/2019				A		100,00 (1)	00 A	\$ 0	550,000 (2)		D				
			Table II - I				quire	contai the fo d, Disj	ined in rm dis _l posed o	this for plays a f, or Ben	m are curre eficial	not requesting noting the noting in the noti	OMB con	spond unle	ess	LC 14	74 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Y	3A. Deemed Execution Dat any	4. Transaction Code (ear) (Instr. 8)		5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Own Form Deri Secu Dire or In	vative rity: ct (D) direct	Beneficia Ownersh (Instr. 4)	
				Code	Code V	(A)		Date Exerci		Expiration Date	n Title	Amount or Number of Shares					
Repor	ting O	wners															

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Harvey Jimmie C/O FORTRESS BIOTECH, INC. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X					

Signatures

/s/ Samuel Berry, Attorney-in-Fact	04/12/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- One-third of the shares will vest on each January 1, 2020, 2021 and 2022, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer.
- (2) The total holdings include 150,000 shares underlying deferred restricted stock units that were previously reported in Table II.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.